Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38470499.
- Also identified by DOI 10.1158/1078-0432.CCR-24-0251.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase I clinical trials. See related article by Ahn et al., p. 2039.
Medical subject headings
- Colorectal Neoplasms
- Mutation
- Polo-Like Kinase 1
- Proto-Oncogene Proteins p21(ras)